At the news
? BEARISHIMPACT 6/10 8-K filed Nov 10, 2026 at 08:06 ET
TriSalus Life Sciences reported Q3 2026 revenue of $12.9M (+11.3% YoY), above the $14.0M consensus, but revised full-year 2026 revenue guidance down to $46M-$48M (2-6% growth vs 2025), well below the prior $54M-$57M range. CMS finalized favorable 2027 reimbursement rate increases for PEDD procedures, but the guidance cut signals slower-than-expected commercial ramp.
- Q3 2026 revenue $12.9M, +11.3% YoY from $11.6M
- Full-year 2026 revenue guidance revised to $46M-$48M from prior $54M-$57M
- GAAP diluted EPS -$0.15 vs -$0.96 YoY; consensus was -$0.13
- Gross margin 86.2% vs 83.5% YoY
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access